Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Role of ‘Atypical’ Bile Acids in Itch

  • Katharina Meinel

Studienabschlussarbeit: Dissertation

Abstract

Background: Pruritus is a common symptom in pediatric and adult patients with chronic cholestatic liver disease (CCLD) like autoimmune sclerosing cholangitis (ASC) and progressive familial intrahepatic cholestasis (PFIC), and the key clinical finding in intrahepatic cholestasis of pregnancy (ICP). Increased bile acid (BA) levels and enhanced autotaxin (ATX) activity are assumed to play a role in the pathophysiology of cholestatic pruritus amongst others, however, the exact etiology remains unknown. Besides the typical human BA, the appearance of ‘atypical’ muricholic acids (MCA) in pediatric and adult CCLD patients has been observed. This study aimed to determine total BA (tBA), total MCA (tMCA) levels and profiles of BA/MCA isoforms in serum of pediatric ASC and PFIC patients with and without pruritus and of pregnant women with and without ICP. ATX antigen levels were studied in serum of all study groups. We hypothesized that a rise of specific BA/MCA correlates with a surge in plasmatic ATX levels. Methods: We investigated fasting serum human BA, MCA, and ATX antigen levels in 27 pediatric CCLD patients aged 1-18 years (ASC n=20 [with pruritus n=6, without pruritus n=14]; PFIC n=7 [with pruritus n=5, without pruritus n=2]) and 23 healthy age-matched controls as well as in 19 ICP patients and 20 healthy pregnant controls. BA profiling was done using high-performance liquid chromatography-tandem mass spectrometry. ATX antigen levels were determined using a commercial ELISA. Pruritus was assessed by a visual analogue scale of pruritus (PVAS) in pediatric patients ≥ 5 years of age. Results: ASC- and PFIC patients exhibited significantly higher tBA (ASC: median: 42.4 µmol/L, interquartile range [IQR]: 18.5-100.1; PFIC median: 262.6 µmol/L, IQR: 32.3-451.7) and tMCA levels, (ASC: median: 0.59 µmol/L, IQR: 0.16-1.00; PFIC: median: 7.39 µmol/L, IQR: 1.31-37.13) than healthy controls (tBA: median: 1.7 µmol/L, IQR: 0.9-3.6; ASC p
Datum der Bewilligung2022
OriginalspracheEnglisch
Gradverleihende Hochschule
  • Medizinische Universität Graz
Betreuer/-inJörg Jahnel (Betreuer*in), Axel Schlagenhauf (Betreuer*in) & Martin Wagner (Betreuer*in)

Dieses zitieren

'